Asceneuron’s tau modifier receives Orphan Drug Designation

Asceneuron SA is an emerging leader in the development of innovative small molecules for the treatment of neurodegenerative diseases. ASN120290 was discovered at Asceneuron. It has recently completed a randomized, double-blind, placebo-controlled phase I study to assess its safety and tolerability of single and multiple doses in healthy young and elderly volunteers. Data from that study will be presented End of July.

The therapeutic potential of ASN120290 has been demonstrated in preclinical studies with a substantial reduction in the build-up of toxic aggregates of tau into neurofibrillary tangles. Neurofibrillary tangles are widely recognized as a key driver of neurodegeneration and clinical symptoms in the majority of dementia cases, including Alzheimer’s disease.

Progressive supranuclear palsy (PSP) is a rare neurological condition that causes severe problems with walking, balance, speech, swallowing and vision as a result of the accumulation of aggregates of the tau protein in the brain. It is estimated that three to six people per 100,000 will develop PSP and there is currently no cure for the disease.

Dirk Beher, chief executive officer and a founder of Asceneuron, commented: “PSP is a rare neurological condition for which there is currently no treatment available. ASN120290 is an orally bioavailable molecule that has the potential of treating the root cause of the neurodegeneration. The granting of Orphan Drug Designation for ASN120290 by the FDA is an important milestone for the team and the company.” 

Orphan Drug status is intended to advance drug development for rare diseases. The FDA provides Orphan Drug Designation to drugs and biologics that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions that affect fewer than 200,000 people in the U.S. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design and an exemption from FDA user fees.

(Press release)